India, June 26 -- Medicenna Therapeutics Corp. (MDNAF) reported a wider loss for the financial year ended March 31, 2026, and provided updates on its anticipated clinical milestones.
Company Profile
Medicenna Therapeutics Corp., is a clinical-stage immunotherapy company focused on developing engineered interleukin-based therapies for cancer, autoimmune, and inflammatory diseases using its proprietary Superkine, BiSKIT, and T-MASK platforms.
The company's pipeline includes MDNA11, an IL-2 Super Agonist being evaluated in Phase 1/2 studies for solid tumors, and bizaxofusp or MDNA55, a Phase 3-ready therapy for recurrent glioblastoma.
Financial Highlights
For the full year, Medicenna reported loss of C$18.4 million, or C$0.22 per share, c...